Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus. Olivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a retrospective and prospective registry by working with over 1,000 healthcare systems to combine electronic health records (EHR) and Patient Reported Outcomes (PROs) in a single spot. There may be sub-studies as an add-on to this parent protocol. The sub-studies will address specific goals of the targeted research activities and will usually include additional information specific to each research study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza raka (jakikolwiek typ) w dokumentacji medycznej
- •Pacjent otrzymuje opiekę medyczną w Stanach Zjednoczonych lub terytoriach USA
- •Możliwość wyrażenia elektronicznej zgody przez pacjenta lub opiekuna prawnego za pośrednictwem platformy
- •Zgoda na dostęp do dokumentacji medycznej
- •Dostęp do smartfona, tabletu lub komputera do udziału zdalnego
Simplified criteria — AI translation
Trial details
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Locations (1)
Tempus AI
Chicago, United States
Trial contact
Olivia Study Team
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.